
William C Mobley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5462953/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair. Annual Review of Neuroscience, 2001, 24, 1217-1281.	5.0	1,146
2	One at a time, live tracking of NGF axonal transport using quantum dots. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13666-13671.	3.3	344
3	Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease. Neuron, 2010, 67, 769-780.	3.8	236
4	Nerve Growth Factor Activates Persistent Rap1 Signaling in Endosomes. Journal of Neuroscience, 2001, 21, 5406-5416.	1.7	215
5	Therapeutic potential of neurotrophic factors for neurological disorders. Annals of Neurology, 1996, 40, 346-354.	2.8	147
6	Nerve Growth Factor Signaling in Caveolae-like Domains at the Plasma Membrane. Journal of Biological Chemistry, 1999, 274, 36707-36714.	1.6	123
7	The Extracellular Domain of p75NTR Is Necessary to Inhibit Neurotrophin-3 Signaling through TrkA. Journal of Biological Chemistry, 2001, 276, 11294-11301.	1.6	76
8	A Functional Dynein–Microtubule Network Is Required for NGF Signaling Through the Rap1/MAPK Pathway. Traffic, 2007, 8, 1503-1520.	1.3	70
9	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 239.	1.0	66
10	Soluble Î ³ -Secretase Modulators Selectively Inhibit the Production of the 42-Amino Acid Amyloid Î ² Peptide Variant and Augment the Production of Multiple Carboxy-Truncated Amyloid Î ² Species. Biochemistry, 2014, 53, 702-713.	1.2	49
11	A Syntenic Cross Species Aneuploidy Genetic Screen Links RCAN1 Expression to β-Cell Mitochondrial Dysfunction in Type 2 Diabetes. PLoS Genetics, 2016, 12, e1006033.	1.5	39
12	Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention. Journal of Experimental Medicine, 2021, 218, .	4.2	39
13	A Î ³ -Secretase Inhibitor, but Not a Î ³ -Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP. PLoS ONE, 2015, 10, e0118379.	1.1	37
14	Expression of neuronal-NOS in developing basal forebrain cholinergic neurons: Regulation by NGF. Neurochemical Research, 1996, 21, 861-868.	1.6	36
15	Pharmacological and Toxicological Properties of the Potent Oral <i>γ</i> -Secretase Modulator BPN-15606. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 31-44.	1.3	36
16	Swedish Nerve Growth Factor Mutation (NGF ^{R100W}) Defines a Role for TrkA and p75 ^{NTR} in Nociception. Journal of Neuroscience, 2018, 38, 3394-3413.	1.7	34
17	Comprehensive Theory of Alzheimer's Disease: The Effects of Cholesterol on Membrane Receptor Trafficking. Annals of the New York Academy of Sciences, 2000, 924, 104-111.	1.8	22
18	Potential Use of Î ³ -Secretase Modulators in the Treatment of Alzheimer Disease. Archives of Neurology, 2012, 69, 1255.	4.9	22

#	Article	IF	CITATIONS
19	Impact of increased <i>APP</i> gene dose in Down syndrome and the Dp16 mouse model. Alzheimer's and Dementia, 2022, 18, 1203-1234.	0.4	19
20	A reverse transcription-polymerase chain reaction study of p75 nerve growth factor receptor gene expression in developing rat cerebellum. International Journal of Developmental Neuroscience, 1994, 12, 255-262.	0.7	8
21	Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators. Bioorganic and Medicinal Chemistry, 2020, 28, 115734.	1.4	8
22	Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders. Annual Review of Pharmacology and Toxicology, 2022, 62, 211-233.	4.2	7
23	Minimized hormones grow in stature. Nature Biotechnology, 1996, 14, 1092-1092.	9.4	2